| PHAT Market Cap History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Below is a table of the PHAT market cap history going back to 10/25/2019:
Also see: PHAT Shares Outstanding History and PHAT YTD Return |
PHAT Market Cap History — Phathom Pharmaceuticals Capitalization Over Time
As of 4/28/2026 Phathom Pharmaceuticals has a market cap of 903.63 million. Investors often follow the PHAT market cap history to compare the size of the company over time.
This page shows PHAT market capitalization trends over time, with 28 market cap datapoints presented, dating back to 10/25/2019.
| PHAT Market Cap History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PHAT Historical Market Cap: +5.52% CAGR 
Mouse over chart for data details
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| PHAT Stock Price Chart |
| About Phathom Pharmaceuticals Inc |
| Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. Co. is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. Co.'s pipeline product candidate, VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. We show 28 historical shares outstanding datapoints in our PHAT shares outstanding history coverage, used to compute PHAT market cap on those dates. Understanding the changing numbers of shares outstanding, the changing share price, and the resulting changing PHAT market cap history over the course of time is important for investors interested in comparing PHAT's market cap history versus its peers. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies, and then calculating their respective market caps. Comparing the share price of PHAT versus a peer is one thing; comparing PHAT market cap versus a peer is a completely different story. Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares), the market cap for a company like PHAT can fluctuate over the course of history. With this page we aim to empower investors researching PHAT by allowing them to research the PHAT market cap history. |
| PHAT Current Stock Quote |
Quotes delayed 20 minutes  Free PHAT Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: The Importance of Market Cap | |
|
Video: The Importance of Market Cap
| PHAT Share Performance |
| Market Cap Peers |
| Phathom Pharmaceuticals (PHAT) is categorized under the Healthcare sector; to help you further research historical market cap numbers, below are some other companies in the same sector:
PHIO Market Cap History PIII Market Cap History PIRS Market Cap History PKI Market Cap History PLRX Market Cap History PLSE Market Cap History PLUR Market Cap History PLXP Market Cap History PMCB Market Cap History PMD Market Cap History More Healthcare companies » |
PHAT Market Cap History | www.MarketCapHistory.com | Copyright © 2017 - 2026, All Rights Reserved
Nothing in MarketCapHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
